Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2024Cancer Research

Abstract 3613: Screening iPSC lines for optimal characteristics of differentiation into immune effector cells for clinical programs

View Full Paper
Ask AI
Bookmark
Share

Authors

BMBarry MorseCentury Therapeutics (United States)ACAmarin CogburnCentury Therapeutics (United States)ACAlex ChialastriUniversity of California, Santa Barbara

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Morse et al. (2024) studied this question.

synapsesocial.com/papers/68e72e40b6db6435876a849bhttps://doi.org/10.1158/1538-7445.am2024-3613
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 2778: Influence of the differentiation strategy on the phenotypic and genotypic features of iPSC derived NK cells2024
  2. 2Abstract 11: Development of innovative off-the-shelf cancer immunotherapies with iPSC-derived CD8-positive T-cells2024 · 1 citations
  3. 3Abstract 39: Preclinical <i>in vitro</i> and <i>in vivo</i> evaluation of CD8αβ+ CD19 CAR iPSCs T cells generated in a TCR signal-independent manner using DLL4/VCAM-coupled microbeads2024
  4. 4Abstract LB313: Advancing iPSC derived CAR NK cell therapy for enhanced solid tumor treatment2026
  5. 5GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy2024 · 19 citations